Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti-C5 therapy.

HemaSphere·2026
Same author

Sustained response after rilzabrutinib discontinuation in multirefractory immune thrombocytopenia.

Blood vessels, thrombosis & hemostasis·2026
Same author

The hunt for a cure: modern medical approaches for immune thrombocytopenia.

Expert review of hematology·2026
Same author

Supportive strategies in thrombocytopenia: Platelet transfusion and beyond.

Blood reviews·2026
Same author

A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia.

The New England journal of medicine·2026
Same author

Towards achieving immune reset in autoimmune cytopenias: Insights from clinical experiences with B cell depleting therapies.

Blood reviews·2026
Same journal

Clinical Trials and Translational Advances in Metabolic Targeting.

Cancer treatment and research·2026
Same journal

Tools and Technologies for Studying Cancer Metabolism.

Cancer treatment and research·2026
Same journal

Cancer and Immune Cells: A Metabolic Battle in the Tumor Microenvironment.

Cancer treatment and research·2026
Same journal

Biomarkers of Cancer Metabolism and Therapeutic Response.

Cancer treatment and research·2026
Same journal

Targeting Metabolism in Cancer Therapy: Inhibitors and Approaches.

Cancer treatment and research·2026
Same journal

Metabolic Reprogramming in Cancer Stem Cells.

Cancer treatment and research·2026
See all related articles

Related Experiment Video

Updated: Jun 7, 2026

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice
03:40

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Romiplostim.

David J Kuter1

  • 1Hematology Division, Massachusetts General Hospital, Boston, MA 02114, USA. kuter.david@mgh.harvard.edu

Cancer Treatment and Research
|November 6, 2010
PubMed
Summary
This summary is machine-generated.

Romiplostim effectively raises platelet counts in over 80% of immune thrombocytopenia (ITP) patients, offering a new treatment option. This thrombopoietin mimetic improves quality of life and reduces the need for other therapies or splenectomy.

Related Experiment Videos

Last Updated: Jun 7, 2026

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice
03:40

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Area of Science:

  • Hematology
  • Pharmacology
  • Oncology

Background:

  • Thrombocytopenia, a low platelet count, affects patients with various conditions like immune thrombocytopenia (ITP).
  • Traditional treatments for thrombocytopenia involved addressing the underlying cause or platelet transfusions.
  • Thrombopoietin (TPO) mimetics represent a novel therapeutic approach for managing thrombocytopenia.

Purpose of the Study:

  • To review the development, biology, and clinical trial data of romiplostim.
  • To evaluate romiplostim's efficacy and safety in treating immune thrombocytopenia (ITP).
  • To provide practical guidance on romiplostim administration for ITP management.

Main Methods:

  • Review of scientific literature and clinical trial data concerning romiplostim.
  • Analysis of romiplostim's pharmacological profile and biological mechanisms.
  • Examination of patient outcomes, including platelet count response and adverse events.

Main Results:

  • Romiplostim demonstrated efficacy in raising platelet counts in over 80% of ITP patients.
  • Patients treated with romiplostim experienced improved quality of life and reduced need for splenectomy or other therapies.
  • Adverse effects were minimal, though long-term theoretical risks include reticulin formation and thromboembolism.

Conclusions:

  • Romiplostim is an effective and well-tolerated treatment for immune thrombocytopenia (ITP).
  • A higher starting dose (3 mg/kg) is recommended for optimal outcomes.
  • Further research will explore romiplostim's potential in chemotherapy-induced thrombocytopenia, hepatitis C-related thrombocytopenia, and myelodysplastic syndromes (MDS).